PHARMACEUTICAL COMPOSITION COMPRISING BOTULINUM NEUROTOXIN PREPARATION INCAPABLE OF BEING SYNAPTICALLY TRANSPORTED, AND USE THEREOF

WIPO Patent Application WO/2010/013494

A1

Disclosed is a botulinum toxin preparation which exhibits no adverse side effect in an area where the preparation is not applied.  Specifically disclosed is a pharmaceutical composition characterized by exhibiting no adverse side effect associated with the synaptic transport in an area other than an area where the preparation is applied.  The pharmaceutical composition comprises, as the main ingredient, a neurotoxin which is derived from Clostridium botulinum incapable of producing an HA protein and has a molecular weight of 150 kDa.  The botulinum neurotoxin is not transported to an area where the pharmaceutical composition is not applied via a nerve axon compared with a neurotoxin derived from Clostridium botulinum type A1, and therefore can be administered at a dose as high as more than 15 U and not more than 25 U per kg body weight.

JP2007533634	Injectable, oral, or topical sustained-release pharmaceuticals
JPH10310534	COMPOSITION FOR TREATING WOUND AND USE OF PEPTIDE
JP3818660	Methods and compositions used for the prevention and treatment of endotoxin-related diseases

AKAIKE NORIO
KATO KEIKO
HARAKAWA TETSUHIRO
TORII YASUSHI
NAGANO AYATAKA
OKUDA SACHIO
NAKAHIRA SHINJI
GOTO YOSHITAKA
GINNAGA AKIHIRO

PCT/JP2009/003661

February 04, 2010

July 31, 2009

Click for automatic bibliography generation  

CHEMO SERO THERAPEUT RES INST (JP)
KUMAMOTO HEALTH SCIENCE UNIVER (JP)
AKAIKE NORIO
KATO KEIKO
HARAKAWA TETSUHIRO
TORII YASUSHI
NAGANO AYATAKA
OKUDA SACHIO
NAKAHIRA SHINJI
GOTO YOSHITAKA
GINNAGA AKIHIRO

A61K38/00; A61P1/04; A61P1/18; A61P3/04; A61P3/10; A61P3/14; A61P5/06; A61P5/16; A61P9/10; A61P9/14; A61P13/02; A61P13/08; A61P13/10; A61P15/00; A61P15/02; A61P15/10; A61P17/02; A61P17/10; A61P17/14; A61P17/16; A61P19/02; A61P19/08; A61P21/00; A61P21/02; A61P25/00; A61P25/02; A61P25/04; A61P25/06; A61P25/08; A61P25/18; A61P25/24; A61P25/28; A61P27/02; A61P27/16; A61P29/00; A61P35/00; A61P43/00

WO2008050866A1	2008-05-02
WO2006013357A1	2006-02-09
WO2006013370A1	2006-02-09
WO2007085728A2	2007-08-02

JP2009132672A

2009-06-18

RYUJI KAJI: "Botulinus Dokuso Chiryo no Kongo no Tenbo", THE JOURNAL OF THE JAPANESE SOCIETY OF INTERNAL MEDICINE, vol. 95, no. 9, 2006, pages 1895 - 1899
TOYOHIKO WATANABE ET AL.: "Hinyokika no Saizensen Shitteokitai Hinyokika no Atarashii Chiryo to Care no Yoten Kakatsudo Boko (OAB) ni Taisuru Chiryo no Saizensen Botulinus Dokuso Bokohekinai Chunyu Ryoho", UROLOGICAL NURSING, vol. 13, no. 7, 10 July 2008 (2008-07-10), pages 693 - 695
MITSUHIKO YOKOYAMA ET AL.: "Kairyogata Botulinus Dokuso o Mochiita Translational Research", THE NISHINIHON JOURNAL OF UROLOGY, vol. 68, no. 6, 2006, pages 234 - 238
KEIJI OGUMA: "Botulinus Dokuso no Idenshi Oyobi Kozo to Kino ni Kansuru Kenkyu", JAPANESE JOURNAL OF BACTERIOLOGY, vol. 60, no. 4, 2005, pages 521 - 530
YONEDA S. ET AL.: "Comparison of the therapeutic indexes of different molecular forms of botulinum toxin type A", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 508, no. 1-3, 2005, pages 223 - 229

HARAKENZO WORLD PATENT & TRADEMARK (2-6 Tenjinbashi 2-chome Kita, Kita-ku, Osaka-sh, Osaka 41, JP)

View/Download PDF      PDF Help

Previous Patent: NOTIFYING METHOD, AND ACCESS CONTROL DEVICE

Next Patent: PHARMACEUTICAL COMPOSITION CONTAINING HIGHLY PURIFIED BOTULINUM NEUROTOXIN THERAPEUTIC AGENT AS ACTI...